227 related articles for article (PubMed ID: 2141040)
1. A study of in vivo immune complex formation and clearance in man.
Davies KA; Hird V; Stewart S; Sivolapenko GB; Jose P; Epenetos AA; Walport MJ
J Immunol; 1990 Jun; 144(12):4613-20. PubMed ID: 2141040
[TBL] [Abstract][Full Text] [Related]
2. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms.
Schifferli JA; Ng YC; Estreicher J; Walport MJ
J Immunol; 1988 Feb; 140(3):899-904. PubMed ID: 2963069
[TBL] [Abstract][Full Text] [Related]
3. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans.
Schifferli JA; Ng YC; Paccaud JP; Walport MJ
Clin Exp Immunol; 1989 Mar; 75(3):329-35. PubMed ID: 2522842
[TBL] [Abstract][Full Text] [Related]
4. Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells.
Emlen W; Burdick G; Carl V; Lachmann PJ
J Immunol; 1989 Jun; 142(12):4366-71. PubMed ID: 2524529
[TBL] [Abstract][Full Text] [Related]
5. Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism.
Craig ML; Bankovich AJ; McElhenny JL; Taylor RP
Arthritis Rheum; 2000 Oct; 43(10):2265-75. PubMed ID: 11037886
[TBL] [Abstract][Full Text] [Related]
6. Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody.
Stewart JS; Sivolapenko GB; Hird V; Davies KA; Walport M; Ritter MA; Epenetos AA
Cancer Res; 1990 Feb; 50(3):563-7. PubMed ID: 2297697
[TBL] [Abstract][Full Text] [Related]
7. Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys.
Reist CJ; Liang HY; Denny D; Martin EN; Scheld WM; Taylor RP
Eur J Immunol; 1994 Sep; 24(9):2018-25. PubMed ID: 8088321
[TBL] [Abstract][Full Text] [Related]
8. Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans.
Madi N; Paccaud JP; Steiger G; Schifferli JA
Clin Exp Immunol; 1989 Nov; 78(2):201-6. PubMed ID: 12412749
[TBL] [Abstract][Full Text] [Related]
9. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
10. CR1 on erythrocytes of Brazilian systemic lupus erythematosus patients: the influence of disease activity on expression and ability of this receptor to bind immune complexes opsonized with complement from normal human serum.
Marzocchi-Machado CM; Alves CM; Azzolini AE; Polizello AC; Carvalho IF; Lucisano-Valim YM
J Autoimmun; 2005 Dec; 25(4):289-97. PubMed ID: 16289666
[TBL] [Abstract][Full Text] [Related]
11. Abnormal immune adherence and elimination of hepatitis B surface antigen/antibody complexes in patients with AIDS.
Madi N; Steiger G; Estreicher J; Schifferli JA
J Immunol; 1992 Feb; 148(3):723-8. PubMed ID: 1530955
[TBL] [Abstract][Full Text] [Related]
12. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
[TBL] [Abstract][Full Text] [Related]
13. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
[TBL] [Abstract][Full Text] [Related]
14. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
Garred P; Michaelsen TE; Aase A; Mollnes TE
J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
[TBL] [Abstract][Full Text] [Related]
15. Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.
Ng YC; Schifferli JA; Walport MJ
Clin Exp Immunol; 1988 Mar; 71(3):481-5. PubMed ID: 2968204
[TBL] [Abstract][Full Text] [Related]
16. Splenic uptake of immune complexes in man is complement-dependent.
Davies KA; Erlendsson K; Beynon HL; Peters AM; Steinsson K; Valdimarsson H; Walport MJ
J Immunol; 1993 Oct; 151(7):3866-73. PubMed ID: 8376807
[TBL] [Abstract][Full Text] [Related]
17. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
18. Immune complex erythrocyte complement receptor interactions in vivo during induction of glomerulonephritis in nonhuman primates.
Birmingham DJ; Hebert LA; Cosio FG; VanAman ME
J Lab Clin Med; 1990 Aug; 116(2):242-52. PubMed ID: 1697615
[TBL] [Abstract][Full Text] [Related]
19. Low expression of erythrocyte complement receptor type 1 in chronic hepatitis C patients.
Kanto T; Hayashi N; Takehara T; Katayama K; Kato M; Akiyama M; Kasahara A; Fusamoto H; Kamada T
J Med Virol; 1996 Oct; 50(2):126-34. PubMed ID: 8915878
[TBL] [Abstract][Full Text] [Related]
20. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes.
Kurlander RJ; Ellison DM; Hall J
J Immunol; 1984 Aug; 133(2):855-62. PubMed ID: 6736648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
